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Nucleic acid-based bioactive substances have recently emerged as a new class of next-
generation therapeutics, but their development has been limited by their relatively weak
delivery into target cells. Cationic liposomes have been studied as a means to enhance the
stability of nucleic acid therapeutics in the bloodstream and improve their cellular delivery.
As nucleic acid therapeutics, siRNA and plasmid DNA have been extensively tested for
delivery using cationic liposomes. This review discusses recent progress in the application
of cationic liposomes for the delivery of nucleic acid therapeutics.
ª 2013 Shenyang Pharmaceutical University. Production and hosting by Elsevier B.V. All
rights reserved.1. Introduction Various nucleic acid-basedmolecules have been studied asAs our understanding of molecular pathogenesis has
improved, nucleic acid therapeutics have received attention
as a modality for modulating the cellular expression levels of
specific genes. Unlike chemical drugs that function by binding
to target proteins, nucleic acid therapeutics can modulate the
pathogenic cellular machinery by controlling the expression
levels of functional proteins. For this modulation of target
protein expression level to occur, however, the nucleic acid
therapeutics must enter the cell membrane and reach the
cytoplasm.x: þ82 2 8822493.
g Pharmaceutical Univer
sevier
ang Pharmaceutical Univnext-generation therapeutics, including plasmid DNA, anti-
sense oligodeoxynucleotides (AS-ODN), small interfering RNA
(siRNA), and micro RNA (miRNA). These molecules share
various physicochemical properties, are larger than chemical
drugs, and carry highly negative charges [1e3], limiting their
cellular delivery. For nucleic acid therapeutics to be success-
ful, therefore, new delivery systems should be developed in
parallel with the identification of appropriate target proteins.
Plasmid DNA, which was among the earliest nucleic acids
considered for therapeutic purposes, has long been studied in
the context of gene therapy [4]. In this context, researcherssity
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fection efficiencies and continuous modulation of gene
expression. However, the tragic death of Gelsinger during a
clinical trial using an adenoviral vector brought home the
chilling notion that viral materials may not be entirely safe [5].
Furthermore, viral vectors have several disadvantages as
pharmaceutical candidates, such as the inconvenience of
needing to design a vector for each target molecule, and a lack
of knowledge regarding the dose dependency of cellular
expression.
Non-viral vectors typically have a lower transfection effi-
ciency than viral vectors, but they have been extensively
studied because they are considered far safer. Nano-
particulate delivery systems, in which cationic lipid nano-
particles are loaded via the negative phosphate groups of
nucleic acids, are a major class of non-viral vectors that show
high productivity and loading efficiency [6e8]. Nano-
particulate systems for carrying nucleic acids may be panop-
tically classified as lipid- or polymer-based nanoparticles, and
each is called a ‘lipoplex’ or ‘polyplex’ after it interacts with
nucleic acids. The cellular delivery of these complexes is
believed to occur via endocytosis followed by endosomal
escape into the cytoplasm [9].
As a delivery system of nucleic acid, cationic liposomes
have advantages. First, the cationic liposomes are biodegrad-
able after administration in vivo. The presence of endogenous
enzymes can breakdown the lipid components of the lipo-
somes. The unparalleled biocompatibility of liposomes among
various nanocarriers resulted in the use of cationic liposomes
for delivery of various siRNAs for in vivo studies [10]. The lipid
composition-dependent modulation of surface charge density
can control the interaction forces with negatively charged
nucleic acids. The inclusion of pegylated lipids or functional
lipids can make possible the diverse surface modification of
liposomes. Moreover, the inclusion of lipophilic chemical
drugs in the lipid bilayers of cationic liposomes can provide
co-delivery of anticancer drug and therapeutic nucleic acids
[11,12]. Given the advantages, cationic liposomes have been
studied for delivery of various nucleic acids such as plasmid
DNA, antisense oligonucleotides and siRNA [13,14].2. Factors that affect the delivery efficiencies
of nucleic acids
For the development of nucleic acid therapeutics using
cationic liposomes, one prerequisite is that the nucleic acids
must be appropriately delivered to target cells and reach the
appropriate subcellular compartment (e.g., the cytoplasm or
nucleus). The delivery efficiencies of cationic liposomes are
known to be affected by the types of cationic and helper lipids,
and their compositions.
2.1. Cationic lipids used for liposomes
Cationic lipids, which are the core components of nano-
particles, have a common structure of a positively charged
head group and one or two hydrophobic tail region(s) made of
hydrocarbon chains or steroid structures. Felgner and col-
leagues reported the synthesis of N-[1-(2,3-dioleyloxy)propyl]-N,N,N-trimethylammonium chloride with a monovalent
cationic head and two hydrocarbon tails, and its use to pre-
pare small unilamellar liposomes [15]. They transfected DNA-
entrapped lipoplexes into mouse L cells and demonstrated
that the cationic lipids neutralized the negatively charged
DNA, giving the cationic lipoplexes a better chance to interact
with negatively charged cell membranes. Since then, various
cationic lipid and lipid-based nanoparticles have been
designed and evaluated for the cellular delivery of nucleic
acids, including DNA, siRNA, miRNA, and AS-ODN.
These new cationic lipids have been identified by a com-
bination of library techniques and rationale-based prediction.
Screening of a lipid-like material library yielded a cationic
lipid of ten carbons and two alkyl chains that was found to be
more effective than other candidates [16]. The screened
cationic lipid was studied for the systemic administration of
apolipoprotein B-specific siRNA to cynomolgus monkeys at a
dose of 6.25 mg/kg, and the expression of apolipoprotein B in
liver tissues was reported to be reduced by more than 50%
over 2 weeks.
Morerecently,Mevelandcolleagues [17] synthesizedvarious
cationic lipids and tried to find a cationic liposome composition
that was effective for plasmid DNA delivery. Among the newly
synthesized cationic lipids, N0,N0-dioctadecyl-N-4,8-diaza-10-
aminodecanoyl glycine amide formulated into cationic nano-
lipoplexes showed the highest transfection efficiency for
plasmid DNA. Furthermore, N0,N0-dioctadecyl-N-4,8-diaza-10-
aminodecanoyl glycine amide was shown to deliver plasmid
DNA to OVCAR-3 and HeLa cell lines more efficiently than the
transfection reagent, Lipofectamine 2000.
The rationale-based prediction of new cationic lipids [18], in
contrast, has been based on the hypothesis that cationic lipids
can interact with natural anionic lipids of the endosomal
membrane after endocytosis, and cone-shaped lipids will
induce destruction of the bilayermembrane. To design cationic
lipids capable of improving transfection efficiency, the authors
controlled the lipid head groups, hydrocarbon domains
and linkers. Using the designed lipids, they showed that
nucleic acidelipid particles composed of 1,2-dilinoleyloxy-3-
dimethylaminopropane-based cationic lipids showed gene-
silencing effects when used to encapsulate siRNA at doses of
0.01 mg/kg in mice and 0.3 mg/kg in cynomolgus monkeys.
A recent structureeactivity relationship study revealed
that a subtle difference in lipid structure could yield distinct
differences in transfection efficiency [19]. The authors
designed and synthesized 1,4,7,10-tetraazacyclododecane
cyclen-based and imidazolium-containing cationic lipid hav-
ing different hydrophobic regions (e.g., cholesterol and dio-
sgenin, respectively). The two cationic lipids were shown to
induce effective gene transfection in HEK293 cells.
2.2. Helper lipids used for liposomes
Neutral lipids have also been routinely used as helpers for
cationic liposomes. For example, theneutral lipid, 1,2-dioleoyl-
sn-glycero-3-phosphoethanolamine (DOPE), is known to be
involved in endosomal escape after the endocytosis of lip-
oplexes [20], and cholesterol (an endogenous lipid) can be
inserted between the lipid bilayers to increase the rigidity of
nanoparticles [21]. To increase in vivo stability, a very general
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conjugated neutral lipids for PEGylation of nanoparticles.
Moreover, neutral helper lipids, such as DOPE have been used
to enhance the delivery efficiencies of cationic liposomes. The
biophysical mechanisms through which DOPE enhances the
efficiency of nucleic acid delivery are still under investigation.
A recent study reported that DOPE-containing lipid mono-
layers exhibited irregular bean-shapeddomains,whereas lipid
monolayers lacking DOPE showed homogenous surfaces [22].
In addition to DOPE, other neutral lipids, including N-laur-
oylsarcosine [23], have been reported to enhance the gene de-
livery efficiency of cationic liposomes.
2.3. Lipid composition
The lipid composition of liposomes can affect the structural
properties of the cationic lipids and their transfection efficiency.
Cationic liposomes composed of 3b-[N-(N0,N0-dimethylamino-
ethane) carbamoyl] cholesterol (DC-Chol) and DOPE are consid-
ered representative liposomes for efficient gene delivery. For
plasmidDNA delivery, themost efficientmolar ratio of DC-Chol
to DOPE was found to be 1:2 [24]. The transfection efficiency of
plasmid DNA decreased as the weight ratio of DC-Chol to
plasmidDNAincreased,with thehighestefficiencyobservedata
ratio of 3:1. A recent study reported the possible dependency of
different endocytic pathways on cationic liposome composi-
tions [25]. Lipoplexes consisting ofplasmidDNAplusDC-Chol or
DOPE-based cationic liposomes were shown to enter the cells
preferentiallyviaraft-mediatedendocytosis,whereas lipoplexes
that included 1,2-dioleoyl-3-trimethylammonium propane
(DOTAP) or dioleoylphosphocholine-based cationic liposomes
were taken up by non-specific fluid-phase macropinocytosis.3. Cationic liposomes for complexation with
various nucleic acids
3.1. Plasmid DNA lipoplexes
For plasmid DNA to be functionally translated within a cell,
the plasmid DNA must undergo effective intracellular traf-
ficking into the cytoplasm, and from there into the nucleus.
Plasmid DNA encoding interleukin 12, a cytokine with anti-
tumor activity, was complexed with cationic liposomes and
tested for its in vivo anticancer effects in a metastatic lung
cancermousemodel [26]. The studied cationic liposomeswere
composed of all-trans-retinoic acid (to enhance the anti-
tumor effects), DOTAP and cholesterol (molar ratio,
10:0.5:0.5) and complexed with interleukin 12-encoding
plasmid DNA. After two intravenous injections with plasmid
DNA (1.2 mg/kg/mouse), the numbers of tumor nodules and
tumor cells were decreased as compared to control group.
In another study, cationic liposomes consisting of O,O0-
ditetradecanoyl-N-(a-trimethyl ammonioacetyl) diethanol-
amine chloride, DOPE and cholesterol were applied for de-
livery of miRNA7-expressing plasmid DNA [27]. The
therapeutic efficacy of the lipoplexes was tested in mice
bearing tyrosine kinase inhibitor-resistant xenograft tumors.
Intratumoral injection of the cationic liposome complex-
encapsulated plasmid (3 mg per mouse) significantlyinhibited tumor growth compared with that in mice receiving
scrambled miRNA-encoding plasmid DNA lipoplexes.3.2. Oligonucleotide lipoplexes
An oligonucleotide is a short nucleic acid polymer of <50
bases. An AS-ODN is a single strand of DNA or RNA that binds
to a complementary mRNA sequence. Since AS-ODNs can
downregulate certain RNAs and suppress target protein
expression, they are considered to have potential as nucleic
acid-based medicines. To develop oligonucleotide-based
therapeutics, however, the instability of oligonucleotides in
physiological environments and their insufficient cellular
uptake must be overcome.
Zhang and colleagues [28] developed cationic liposomes
composed of dimyristoyl 1,2-diacyl-3-trimethylammonium-
propane, phosphatidylcholine, and cholesterol for systemic
delivery of AS-ODNs against Raf-1 protein serine/threonine
kinase (a known target signaling protein for cancer treat-
ment). They observed that systemic administration of AS-
ODNs complexed to cationic liposomes reduced Raf-1 pro-
tein expression in liver and tumor tissues, and inhibited the
growth of PC-3 tumors in mice.
In another study, Bcl2-specific AS-ODNs were complexed
to protamine and cationic liposomes composed of DC-
Chol, phosphatidylcholine, and polyethylene glycol-
distearylphosphatidylethanolamine [29]. The liposomes
significantly increased the cellular uptake of Bcl-2 AS-ODNs,
resulting in significant downregulation of Bcl-2 protein levels.
Notably, the study introduced a new method of forming lip-
oplexes using a multi-inlet microfluidic hydrodynamic
focusing system, which yielded a smaller mean size and
narrower size distribution compared to lipoplexes prepared
with the conventional mixing method.
AS-ODNs and cationic liposomes were studied for the
treatment of atopic dermatitis [30]. Interleukin-13-targeting
AS-ODNs were complexed to cationic liposomes composed
of DOTAP and sodium cholate, and applied topically to skin
lesions of mice with atopic dermatitis. This treatment dose-
dependently alleviated the atopic dermatitis, with maximal
inhibition observed in response to 200 mg of interleukin-13 AS-
ODNs.
CpG ODNs, which are synthetic single-stranded DNAs
known to function as a vaccine adjuvant [31], have also been
delivered using cationic liposomes. A Th1-mediated immune
response is promoted by the interactionof CpGODNswith toll-
like receptor 9, and CpG ODNs reportedly possesses antitumor
activity.Cationic liposomeshavebeenformulated toefficiently
deliver CpGODNs to boost immune responses or treat cancers.
CpGODNswere complexed to cationic liposomes composed of
N-[1-(2,3-dioleyloxy)propyl]-N,N,N trimethylammonium chlo-
ride, or N-[1-(2,3-dioleoyloxy) propyl]-N,N,N-trimethylammo-
nium chloride and cholesterol. The intranasal administration
of cationic liposome-complexed CpG ODNs was found to pre-
vent pulmonary metastasis, suppress proliferation of tumor
cells in the lung, and prolong the survival time of mice more
efficiently than naked CpG ODNs. Furthermore, the complex-
ation of CpG ODNs with cationic liposomes composed of N-[1-
(2,3-dioleyloxy)propyl]-N,N,N-trimethylammonium chloride
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of natural killer cells [32].
Lipoplexes composed of CpG ODNs and cationic liposomes
have been tested for their ability to prevent melioidosis, an
infectious disease caused by Burkholderia pseudomallei [33].
CpG ODNs complexed to cationic liposomes were adminis-
tered tomice at a dose of 100 mg per animal, and themicewere
challenged 30 days later with B. pseudomallei. The results
revealed that DOTAP liposomes complexed to CpG ODNs
prevented B. pseudomallei infection more effectively than
DOPC liposomes complexed to CpG ODNs.
3.3. SiRNA lipoplexes
The RNA interference (RNAi) pathway allows siRNAs and
miRNAs to negatively regulate protein expression [34]. SiRNAs
are double-stranded RNAs of 21e23 nucleotides that induce the
silencing of homologous target mRNAs. For their action,
double-stranded siRNAs separate into two single-stranded
RNAs: the passenger and guide strands. The passenger strand
is degraded by argonaute-2, while the guide strand is incorpo-
rated into an RNAi-induced silencing complex, which binds the
mRNA complementary to the guide strand and cleaves it. SiR-
NAs appear to have great potential to treat diverse diseases, as
they can easily downregulate various target mRNAs regardless
of their location (i.e., in the nucleus or the cytoplasm), and their
specific binding suggests that they will induce fewer side ef-
fects than conventional chemical drugs. As a novel nucleic
acid-based strategy, siRNA-based treatments have several ad-
vantages over conventional chemical drugs. However, some
challenges must be overcome to facilitate the development of
siRNA-based therapeutics, including the need to identify
proper target genes and develop optimized delivery systems.
A number of researchers have sought to enhance the
cellular delivery and gene-silencing efficiencies of siRNA
using cationic liposomes. For example, cationic liposomes
composed of DC-6-14, DOPE, and cholesterol were formulated
to deliver siRNAs specific for firefly luciferase [35]. Trans-
fectionwas improvedwhen the cationic lipids and siRNAwere
mixedwith constant and intense agitation, indicating that the
method of loading the siRNA onto cationic liposomes could
modulate the efficiency of transfection.
The therapeutic applications of siRNA lipoplexes vary
depending on the target protein. To treat immunological dis-
ease, siRNAs specific for glyceraldehyde 3-phosphate dehy-
drogenase (GAPDH) were complexed to cationic liposomes
containing 1,2-dilinoleyl-4-(2-dimethylaminoethyl)-[1,3]-diox-
olane, 1,2-distearoyl-sn-glycerol-3-phosphocholine (DSPC)
and cholesterol [36]. Mice were treated with the complexes
(5 mg/kg siRNA), and after 4 days, they showed w40% less
GAPDHproduction inmacrophages anddendritic cells fromthe
peritoneal cavity, and w60% GAPDH expression in spleen
derived antigen-presenting cells.
In other work, heavy chain ferritin specific-siRNAs were
complexed to cationic liposomes and locally administrated to
human glioma U251-bearing mice [37]. Intratumoral injection
of ferritin-specific siRNAs complexed to cationic liposomes
composed of DC-Chol and DOPE reduced tumor growth to a
degree comparable to that seen with carmustine (a DNA-
alkylating agent that is primarily used in glioma therapy).Argonaute-2-specific siRNAs, which have been shown to
induce apoptosis, were delivered using PEGylated cationic
liposomes composed of DC-6-14, 1-palmitoyl-2-oleoyl-sn-
glycero-3-phosphocholine, DOPE, and 1,2-distearoyl-sn-
glycero- 3-phosphoethanolamine-N-(methoxy[polyethylene
glycol]-2000) [38]. For treatment of Lewis lung carcinoma-
bearing mice, the complexes were intravenously injected
into tumor cell-inoculated mice (1 mg/kg every other day for
five doses). The repeated administration of these complexes
reduced the expression of argonaute-2 in tumor tissues and
significantly suppressed tumor growth.
3.4. MiRNA lipoplexes
MiRNAs are short (w22mer) noncoding RNAs that are found in
eukaryotic cells [34] and act as biological regulators by binding
to complementarymRNA sequences. AnmiRNA is transcribed
from its encoding nuclear gene in the form of a primary
miRNA, which is several hundred nucleotides long. The RNase
III enzyme, Drosha, processes the primary miRNA into a pre-
miRNA (w70 nucleotides long) that carries a characteristic
hairpin loop. The pre-miRNA then moves to the cytoplasm,
where the RNase III enzyme, Dicer, produces mature miRNAs
and passenger strands. Finally, the mature miRNAs are
incorporated into the RNAi-induced silencing complex for
degradation of their target mRNAs.
Cationic liposomes consisting of 1,2-di-O-octadecenyl-3-
trimethylammonium propane, cholesterol, and D-a-toco-
pheryl polyethylene glycol 1000 succinate were shown to
efficiently deliver pre-miRNA-133b, resulting in a 2.3-fold in-
crease in the expression of mature miRNA-133b and an 1.8-
fold decrease in Mcl-1 protein in A549 non-small lung cancer
cells, compared with cells that received the control siPORT
NeoFX transfection agent [39]. ICR mice that received cationic
liposomes with pre-miRNA-133b (1.5 mg/kg) by tail-vein in-
jection showed w52-fold higher mature miRNA-133b expres-
sion in lung tissues compared tomice that received scrambled
pre-miRNA-containing cationic liposomes.
Another recent study [40] demonstrated that systemic de-
livery of cationic liposomes carrying tumor-suppressor miRNA
had the potential to treat cancer. Cationic liposomes containing
1,2-dioleoyl-3-trimethylammonium-propane, cholesterol, and
1,2-dioleoyl-sn-glycero-3-phosphoethanolamine-N-[methoxy
(polyethylene glycol)-2000] were complexed to miRNA-34a or
the miRNA-143/145 cluster. MiRNA-34a is a component of the
p53 transcriptional network and regulates cancer stem cell
survival, and was thus selected as a tumor suppressor, while
themiR-143/145 cluster is known to suppress the expression of
KRAS2 and its downstream effector, Ras-responsive element
binding protein-1. Intravenous delivery of miRNA-34a or
miRNA-143/145 using cationic liposomes inhibited tumor
growth in both a subcutaneous xenograft model and an
orthotopic pancreatic cancer xenograft model.4. Recent progress in cationic liposomes
Although various cationic lipid-based delivery systems have
been used for the in vitro and in vivo delivery of nucleic acids,
there are still challenges thatmust be overcome, including the
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geting, and low anti-tumor activity. In an effort to address
these limitations, researchers have developed improved
cationic lipids by combining novel synthesized lipids, target-
ing ligands, and/or anti-tumor drugs.4.1. Engineered lipid-based systems
The engineering of new lipids has been investigated as a
means to improve the delivery efficiencies of nucleic acids. For
example, researchers synthesized the cholesterol-derivative
cationic lipid, 3-b(N-(N0,N0-dimethyl, N0-hydroxyethyl amino-
propane) carbamoyl) cholesterol iodide (DMHAPC-Chol), and
showed that it could promote the delivery of vascular endo-
thelial growth factor (VEGF)-specific siRNAs into tumor cells
[41]. Structurally, the lipid has a biodegradable carbamoyl
linker and a hydroxyethyl group in its polar amino head
moiety. Cationic liposomes composed of DMHAPC-Chol and
DOPE in equimolar proportion delivered VEGF siRNA to A431
and MDA-MB-231 cells and exhibited >90% effective silencing
of VEGF protein expression. In another study, a cholesterol-
based polycationic liposomal formulation in which the hy-
drophilic part of spermine was conjugated with one or two
cholesterol residues was developed for the delivery of siRNA
[42]. Liposomes consisting of synthetic polycationic lipids and
DOPEwere shown to silence the expression of enhanced green
fluorescent protein (EGFP) in EGFP-expressing HEK293 cells.
In addition to cholesterol derivatives, arginine-based
cationic lipids have also been studied for siRNA delivery.
Poly-L-arginine lipid derivatives formulated with poly-L-argi-
nine-conjugated polyethylene glycol lipids, DOTAP, DOPE, and
cholesterol were synthesized for enhanced delivery of siRNA
[43]. The liposomes successfully reduced the expression of
green fluorescent protein (GFP) and showed low cytotoxicity in
H4II-E and HepG2 cells. In other work, the arginine derivative,
N,N-distearyl-N-methyl-N-2-(N0-arginyl) aminoethyl ammo-
nium chloride, was used for cationic liposome formulation
with cholesterol [44]. The cationic liposomes were complexed
to c-Myc siRNA and intravenously administered to B16F10
melanoma-bearingmice (1.2 mg/kg once a day for three days),
resulting in the sensitization of B16F10 tumors to paclitaxel.
Another study suggested the use of arginine-based DiLA2
lipids as a cationic liposome component for apolipoprotein B-
specific siRNA delivery [45]. Following intravenous adminis-
tration to mice (ED50, 0.1 mg/kg), cationic liposomes prepared
from DiLA2 and DOPE showed the potential to suppress
apolipoprotein B mRNA expression in the liver. After single
systemic dose, the maximal reduction (w80%) in the levels of
target mRNA was observed at day 2 post-dose, and >50%
reduction of target mRNA was sustained up to day 9 post-
dose.
Alkaline amino acid-based cationic liposomes have been
studied for their potential to enhance the stability of cationic
liposomes in serum [46]. Lysinylated cholesterol, histidiny-
lated cholesterol, and argininylated cholesterol were tested,
and lysinylated cholesterol and argininylated cholesterol lipid
based-cationic liposomes showed more efficient transfection
plasmid DNA in serum-containing media.Conjugates of spermine with cholesterol or long-chain
hydrocarbons have been formulated into liposomes.
Spermine-tagged cationic lipids and DOPE (1:1 ratio) were
complexed to EGFP-encoding plasmid DNA or RNA for electro-
pulsing into immature dendritic cells or dendritic cell pro-
genitors [47]. Intravenous administration of the nucleic acid-
pulsed dendritic cells to tumor-bearing mice was found to
induce the production of antitumor cytokines, suggesting that
cationic liposomes could be used to generate nucleic acid-
pulsed dendritic antitumor vaccines.
Recently, a biomimetic thioether lipid library was screened
using thiol-yne “click” chemistry, which conjugates cationic
thioether amine lipids with two hydrophobic alkyl thiols [48].
One DOPE-containing lipid formulation was found to increase
the uptake of GFP-specific siRNAs in various cell types.
Since cationic liposomes typically show relatively high
cytotoxicities, various strategies have been proposed to
reduce their toxicity and enhance their in vivo delivery of
siRNA. To this end, researchers have coated the cationic
lipoplexes with non-toxic and biodegradable anionic poly-
mers, such as poly-L-glutamic acid sodium salt, poly(acrylic
acid) sodium salt, dextran sulfate sodium salt, alginic acid
sodium salt, hyaluronic acid sodium salt, heparin sulfate
sodium salt, and carboxymethylcellulose sodium salt [49].
Among these anionic polymers, polyglutamate did not have
any obvious toxicity over a wide range of sizes, and the
coated cationic liposomes showed enhanced delivery of
siRNA in the liver and lung tissues compared to uncoated
lipoplexes (Fig. 1a).
4.2. Ligand modifications for targeted delivery
Although cationic liposomes have the potential to deliver
nucleic acids in vivo, their delivery to the specific target site
remains a major challenge. To enhance the distribution of
nucleic acid-bearing cationic liposomes to target tissues, re-
searchers have modified the liposome surfaces with peptides
and small molecules.
For example, Arg-Gly-Asp (RGD) peptide-modified lipo-
somes were studied for their ability to enhance the delivery of
nucleic acids to integrin receptor-expressing cells [50]. RGD-
modified cationic liposomes loaded with p-glycoprotein-spe-
cific siRNAs showed higher delivery to integrin receptor-
expressing human breast cancer MCF7/A cells, resulting in
significant silencing of p-glycoprotein. Consistent with this,
molecular imaging revealed a higher distribution of RGD-
modified cationic liposomes and siRNA lipoplexes in MCF7/A
tumor tissues compared to adjacent normal tissues in a
mouse model. In a recent study, liposomal surfaces were
modified with both cyclic RGD and octaarginine to utilize the
integrin receptor-binding effects of cyclic RGD and the cell-
penetrating effects of octaarginine (Fig. 1b) [51]. The dual-
ligand modified cationic liposomes showed increased
cellular uptake into integrin avb3-expressing cells and more
effective transfection of luciferase-encoding plasmid DNA.
The conjugation of lipids to bioactive small molecules (e.g.,
folic acid) has been investigated for the targeted delivery ofnu-
cleic acids. For example, a lipoplex formed by the non-covalent
association of folic acid to a 1-palmitoyl-2-oleoyl-sn-glycero-3-
Fig. 1 e Strategies for cationic liposome-based nucleic acid delivery. (a) The surface of the siRNA lipoplex is coated with the
anionic polymer, polyglutamate. (b) The targeted delivery of plasmid DNA is facilitated by a dual-ligand system composed of
a specific cRGD ligand and a stearylated octaarginine. (c) To increase anticancer activity, anticancer siRNAs and a chemical
drug are co-loaded in trilysinoyl oleylamide-based liposomes.
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ced the transfection efficiency of plasmid DNA encoding thymi-
dine kinase and inhibited TSA and SCC7 cell growth in vitro [52].
These folate-associated lipoplexes showed higher antitumor ef-
ficacy in mice bearing SCC7 tumor xenografts. In another
approach, folic acid-tagged cationic liposomes were complexed
with calf thymus DNA for activation of macrophages, and
showedhigherdeliveryofDNAtofolatereceptor-expressingcells
as compared toplain cationic liposomeswithout folic acid [53]. In
tumor-bearing mice, folate-tagged lipoplexes induced the pro-
duction of interferon-g and interleukin-6 and prolonged survival
compared to that in mice treated with folate-free lipoplexes.
Glycyrrhetinic acid has been used to target hepatocellular
carcinoma cells, based on a study showing that protein kinase
C, a binding target of glycyrrhetinic acid, is expressed more
highly on the surface of hepatocellular carcinoma cells
compared to adjacent non-tumor liver cells [54]. A glycyr-
rhetinic acidepolyethyleneglycolecholesterol conjugate was
synthesized and used to formulate cationic liposomes with
DOTAP and cholesterol [55]. These liposomes showed higher
capacities to form complexes with GFP-expressing plasmid
DNA and enhance the transfection of plasmid DNA into he-
patocellular carcinoma cells, compared to control cationic li-
posomes that lacked glycyrrhetinic acid.
Since mannose receptors are found on macrophages,
mannose has been used to modify cationic liposomes formacrophage delivery. To suppress osteoclastogenesis, which
is induced by activated macrophages, mannosylated cationic
liposomes were complexed with the double-stranded oligo-
nucleotide, NFkB decoy [56]. Mannose-cationic liposome/NFkB
decoy complexes efficiently induced NFkB activation and
inhibited the production of tumor necrosis factor-a. In
another study, macrophage-targeting NFkB decoys loaded in
mannosylated cationic liposomes were used to prevent
lipopolysaccharide-induced lung inflammation [57]. After
intratracheal administration to a rat model of lung inflam-
mation, mannose-tagged cationic liposome/NFkB decoy
complexes significantly downregulated the expression of
NFkB and reduced the release of tumor necrosis factor-a and
interleukin-1b.
Anisamide-modified cationic liposomes were studied for
their ability to confer targeted delivery of oligonucleotides to
sigma receptor-expressing cells [58]. Splice-switching oligo-
nucleotides (SSOs) are single-strand oligonucleotides that
bind to a splice site or splicing enhancer, blocking access to
the endogenous splicing machinery and generating an alter-
nate version of the mature mRNA. In a mouse model of lung
metastasis, the systemic administration of anisamide-
modified cationic lipoplexes loaded with Bcl-x SSO reduced
tumor growth.
Dexamethasone is known to have a nucleus-targeting
function. To enhance the nuclear transport of plasmid DNA,
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and mixed with DOPE (1:1) to form liposomes [59]. The
PAMAM-dexamethasone/DOPE-based cationic liposomes
enhanced the expression of plasmid DNA in HEK293 cells and
showed reduced cytotoxicity compared to polyethylenimine
(m.w. 25,000).
Overall, the modification of targeting ligands can help
achieve specific targeting and avoid non-specific distribution
to the liver and other tissues. From the perspective of
commercialization, however, ligand-tailoring technologies
still face many hurdles, including the need for more stream-
lined manufacturing processes and improved quality control.
4.3. Co-delivery with chemosensitizers
To enhance anticancer activity, researchers have examined
co-delivery approaches in which anticancer siRNAs and
chemical drugs are co-loaded into cationic liposomes. For
example, the mitogen-activated protein kinase inhibitor,
PD0325901, was encapsulated in cationic liposomes composed
of N,N-dioleylglutamide cationic lipids, DOPE and cholesterol,
and complexed with Mcl-1 siRNAs by electrostatic interaction
[11]. Intratumoral administration of these cationic liposomes
significantly suppressed tumor growth in mouse model. In
another study, trilysinoyl oleylamide-based cationic lipo-
somes were developed for the co-delivery of Mcl-1 siRNA and
the anticancer drug, suberoylanilide hydroxamic acid (Fig. 1c)
[12]. The use of drug-loaded PEGylated liposomes complexed
to Mcl-1 siRNA improved the in vivo anticancer efficacy in
tumor-bearing mice compared to monotherapy with Mcl-1
siRNA lipoplexes or suberoylanilide hydroxamic acid-
containing liposomes.
Finally, doxorubicin-entrapped cationic liposomes were
complexed to plasmid DNA encoding the phosphorylation-
defective mouse survivin protein, which is an oncogenic
protein encoded by BIRC5 gene, and serves as amember of the
inhibitor of apoptosis family [60,61], threonine 34-alanine
mutant, and then modified with truncated human basic
fibroblast growth factor peptide to create selectivity for fibro-
blast growth factor receptor-expressing cells [62]. Significant
reductions in tumor growthwere observed in lung carcinoma-
bearing C57BL/6 mice following the intravenous administra-
tion of these complexes.5. Current challenges to clinical applications
Despite recent progress, lipoplexes of cationic liposomes and
nucleic acids still suffer from several limitations. One is their
low stability in the bloodstream, which is caused by the
characteristics of cationic lipids. Until they reach their target
cells, cationic lipid components can interact with serum pro-
teins, potentially disrupting the integrity of liposomal struc-
tures or forming aggregates that are too large to be taken up by
cells. To increase the in vivo stability of lipoplexes in the blood,
researchers often include PEG-conjugated lipids and choles-
terol as components of the cationic liposomes. Another limi-
tation is the relatively weak delivery of nucleic acids into
target cells. For anti-cancer therapy, enhanced retention and
permeability may serve as an initial driving force for thedelivery of lipoplexes to tumor tissues [63]. Once in the tumor
tissues, the effective recognition of tumor cells and intracel-
lular delivery should proceed.
Among the potential cationic lipid-encapsulated nucleic
acid therapeutics, the current leader is Atu027 of Silence
Therapeutics [64,65], which consists of AtuRNAi (targeting
protein kinase N3) and AtuPLEX (based on cationic lipids).
Atu027 was demonstrated to be safe and has completed a
Phase I study for the treatment of solid cancer. Currently, re-
searchers are planning a Phase Ib study in which Atu027 will
be combined with chemotherapy.6. Conclusion
Numerous cationic lipid-based vehicles have been developed
for nucleic acid therapeutics, and substantial progress has
been made toward improving their efficacy in vivo. Several
clinical trials of siRNA-based therapeutics are ongoing, sug-
gesting that nucleic acids may emerge as new class of thera-
peutics in the near future. Their success will rely on the
development of effective delivery systems. Despite recent
progress, however, we still need to continue developing a
variety of safe, stable, and effective cationic lipid-based car-
riers that are capable of delivering nucleic acids to the proper
target sites and cells.
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